|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
D
|
|
INDICATIONS:
|
|
Arthritis, rheumatoid |
|
Rejection, renal transplant, prophylaxis |
| |
|
|
SIDE EFFECTS:
|
|
Leukopenia or infection |
|
megaloblastic anemia |
|
Hepatitis or biliary stasis |
|
thrombocytopenia |
|
Gastrointestinal hypersensitivity reaction |
|
hepatic veno-occlusive disease |
|
hypersensitivity |
|
pancreatitis, hypersensitivity |
|
pneumonitis |
|
sores in mouth and on lips |
|
Loss of appetite |
|
nausea or vomiting |
|
Skin rash |
|
Bone marrow depression, delayed |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
>> Chickenpox, existing |
|
>> Herpes zoster |
|
>> Gout |
|
>> Hepatic function impairment |
|
>> Infection |
|
Pancreatitis |
|
>> Renal function impairment |
|
>> Sensitivity to azathioprine |
|
>> Xanthine oxidase deficiency, severe |
|
|
ADULT DOSE:
|
|
Transplant rejection, organ (prophylaxis)-Initial: Intravenous 3 to 5 mg (base) per kg of body weight a day prior to , during, or soon after surgery, the dosage being adjusted to maintain the homograft without causing toxicity.
Maintenance: Intravenous, 1 to 3 mg (base) per kg of body weight a day. |
|
MAXIMUM ADULT DOSE:
|
|
|
|
PEDIATRIC DOSE:
|
|
Transplant rejection, organ (prophylaxis)-Initial: Intravenous 3 to 5 mg (base) per kg of body weight a day prior to , during, or soon after surgery, the dosage being adjusted to maintain the homograft without causing toxicity.
Maintenance: Intravenous, 1 to 3 mg (base) per kg of body weight a day. |
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|
|